Creative Capital Management Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Creative Capital Management Investments’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$759	Buy	+30	New	+$660	﹤0.01%	1174

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Creative Capital Management Investments's ACAD Position: Q2 2026 in Review

Creative Capital Management Investments opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 30 shares worth $759. The stake represents ﹤0.01% of the portfolio and ranks #1174 among its holdings.

354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Creative Capital Management Investments held 30 shares of Acadia Pharmaceuticals worth $759 as of Q2 2026.
Acadia Pharmaceuticals was a new Creative Capital Management Investments position in Q2 2026.
Acadia Pharmaceuticals made up ﹤0.01% of Creative Capital Management Investments's portfolio in Q2 2026, its #1174 holding.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Creative Capital Management Investments's 13F filing for Q2 2026, filed 24 Jul 2026.